There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (NASDAQ: IRTC), Smith & Nephew Snats (NYSE: SNN) and Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) with bullish sentiments.
Irhythm Technologies (NASDAQ: IRTC)
Canaccord Genuity analyst Jason Mills reiterated a Buy rating on Irhythm Technologies (NASDAQ: IRTC) yesterday and set a price target of $80. The company’s shares opened today at $67.99, close to its 52-week high of $69.99.
According to TipRanks.com, Mills is a top 25 analyst with an average return of 27.5% and a 76.9% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Staar Surgical Company.
Irhythm Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $72.
See today’s analyst top recommended stocks >>
Smith & Nephew Snats (NYSE: SNN)
In a report released yesterday, Kyle Rose from Canaccord Genuity maintained a Buy rating on Smith & Nephew Snats (NYSE: SNN), with a price target of $42. The company’s shares opened today at $36.30.
Rose noted:
“We maintain our BUY rating following marketing meetings with management. We recently hosted a day of investor meetings with Smith & Oie, VP IR, and came away with a better understanding of investor sentiment as well as the drivers of growth for the company in 2018 and beyond. Unsurprisingly, investor interest was focused on the incoming CEO, Namal Nawana, who took the helm at SNN on May 7, insight into the early execution of the Navio robotic platform, and the puts and takes of the Q1 sales results and updated 2018 outlook. BUY.”
According to TipRanks.com, Rose is a 4-star analyst with an average return of 11.2% and a 57.6% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Stryker Corporation.
Smith & Nephew Snats has an analyst consensus of Hold, with a price target consensus of $42.
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN)
In a report released yesterday, Sumant Kulkarni from Canaccord Genuity assigned a Buy rating to Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN), with a price target of $35. The company’s shares opened today at $29.88.
Kulkarni commented:
“We are updating our model after BHVN reported its 1Q18 yesterday (5/15). We did not make any substantial changes to our model, but are rolling forward our discount period to mid-2019E from the end of 2018E, which leads to our one-year price target going up from $34 to $35. Recall that Phase 3 data are now out of the way for both BHVN’s rimegepant (treatment of acute migraine; see here and here) and competitor Allergan’s ubrogepant (see here). We now believe investor focus has shifted to long-term safety data and results from the rimegepant orally-dissolving tablet (ODT) formulation, both of which BHVN expects to report in 4Q18; the company remains on track to file a new drug application (NDA) for rimegepant in 2019. We also note Allergan expects to complete its long-term safety trial on ubrogepant in 2H18 and file an NDA in 2019.”
According to TipRanks.com, Kulkarni is a 1-star analyst with an average return of 0.1% and a 45.8% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Alder Biopharmaceuticals, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co Ltd is Strong Buy and the average price target is $31.67, representing a 6.0% upside.
In a report released yesterday, Needham also maintained a Buy rating on the stock with a $36 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
